Category: Mergers and Acquisitions

August 19, 2020

Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash. This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a […]

June 23, 2020

Members of the European Commission, the European Medicines Agency, and the US FDA held their 2020 bilateral regulatory meeting virtually from June 18–19, 2020. The agencies discussed ongoing joint initiatives and strategies for collaborating in the future. The agencies, which […]

June 19, 2020

PDS Biotechnology said June 17 that it signed an agreement with Farmacore Biotechnology to co-develop Versamune®-CoV-2FC. PDS and Farmacore agreed to accelerate development of the vaccine candidate into Phase 1 clinical testing in Brazil, with initial financial support to be […]

June 4, 2020

Novavax, a late-stage biotechnology company developing the NVX-CoV2373 coronavirus vaccine candidate against SARS-CoV-2 has secured two manufacturing agreements for large-scale GMP (good manufacturing practice) manufacture of components of the vaccine candidate. NVX CoV2373 is engineered from the genetic sequence of […]

June 3, 2020

Officials at Cytiva say the company will work with Entos Pharmaceuticals to optimize a clinical manufacturing solution for the company’s Covigenix COVID-19 DNA vaccine candidate. Entos develops next generation nucleic acid medicines using its Fusogenix platform, which uses a novel […]

April 13, 2020

Efforts to shift more production of pharmaceuticals and APIs to the United States as a strategy for reducing drug shortages and ensuring access to needed medicines has gained strength in the White House and on Capitol Hill. The recent $2-trillion […]

April 7, 2020

Servier has entered into a definitive agreement to acquire the antibody discovery biotech Symphogen A/S. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody […]

March 24, 2020

Astellas Pharma plans to expand its pipeline of next-gen immuno-oncology treatments through a collaboration with CytomX that could generate more than $1.68 billion for the South San Francisco, CA, developer of antibody therapeutics. Through the collaboration, announced Monday night, Astellas […]

March 10, 2020

Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across […]

March 4, 2020

Alnylam Pharmaceuticals and Vir Biotechnology have teamed up to develop RNAi therapeutics against the coronavirus behind the COVID-19 outbreak. The collaboration builds on Alnylam synthesis of siRNAs that target highly conserved regions of coronavirus RNA. Vir and Alnylam joined forces […]

March 3, 2020

Avectas, a cell engineering technology business, and CCRM, a leader in developing and commercializing cell and gene therapies, have entered into a collaboration to accelerate the translation of Avectas’ non-viral cell engineering platform (Solupore) into the clinic. Cell and gene […]

February 27, 2020

Another high-profile member of the Spark Therapeutics leadership team is departing the company ahead of its merger with Swiss pharma giant Roche. After four years with the gene therapy company, Chief Medical Officer Kathleen Reape will resign her position. Reape […]